Icaritin promotes the osteogenesis of bone marrow mesenchymal stem cells via the regulation of sclerostin expression Corrigendum in /10.3892/ijmm.2023.5277

Wei,Qiushi; Wang,Bin; Hu,Hailan; Xie,Chuhai; Ling,Long; Gao,Jianliang; Cao,Yanming

doi:10.3892/ijmm.2020.4470

Icaritin promotes the osteogenesis of bone marrow mesenchymal stem cells via the regulation of sclerostin expression

Corrigendum in: /10.3892/ijmm.2023.5277

Authors:
- Qiushi Wei
- Bin Wang
- Hailan Hu
- Chuhai Xie
- Long Ling
- Jianliang Gao
- Yanming Cao
View Affiliations

Affiliations: Hip Preserving Ward, No. 3 Orthopedic Region, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510407, P.R. China, Department of Orthopedics, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, P.R. China
Published online on: January 20, 2020 https://doi.org/10.3892/ijmm.2020.4470
Pages: 816-824
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Icaritin, a metabolite of icariin, is a potent promoter of bone marrow‑derived mesenchymal stem cells (BMSCs) osteogenesis, but the underlying mechanisms remain unclear. To examine the effects of icaritin on osteogenic differentiation, BMSCs were exposed to osteogenic induction medium with or without icaritin pretreatment in the present study. It was identified that icaritin (0.01‑1 µM) exhibited no cytotoxicity on the proliferative abilities of the BMSCs. Icaritin at 1 µM increased alkaline phosphatase activity, mineral deposition and osteoblast‑specific gene expression. Treatment with 1 µM Icaritin upregulated osteocalcin, RUNX family transcription factor 2, tissue‑nonspecific alkaline phosphatase and β‑catenin, and suppressed sclerostin (SOST) gene expression in different stages of osteogenic differentiation. It was also demonstrated that SOST overexpression inhibited icaritin‑induced osteogenesis. The western blot analysis data suggested that ICI 182780, which causes estrogen receptor α (ERα) degradation, reversed the icaritin‑induced decrease in SOST expression, which was inconsistent with the results of immunofluorescence analysis. In conclusion, icaritin was demonstrated to promote the osteogenesis of hBMSCs by downregulating SOST expression, and icaritin‑induced suppression of SOST was regulated in part via the Wnt/β‑catenin/ERα axis.

View Figures

View References

1	Liu C, Zhang H, Tang X, Feng R, Yao G, Chen W, Li W, Liang J, Feng X and Sun L: Mesenchymal stem cells promote the osteo-genesis in collagen-induced arthritic mice through the inhibition of TNF-α. Stem Cells Int. 2018:40690322018. View Article : Google Scholar
2	Huang Z, Cheng C, Cao B, Wang J, Wei H, Liu X, Han Y, Yang S and Wang X: Icariin protects against glucocorticoid-induced osteonecrosis of the femoral head in rats. Cell Physiol Biochem. 47:694–706. 2018. View Article : Google Scholar : PubMed/NCBI
3	Wei Q, He M, Chen M, Chen Z, Yang F, Wang H, Zhang J and He W: Icariin stimulates osteogenic differentiation of rat bone marrow stromal stem cells by increasing TAZ expression. Biomed Pharmacother. 91:581–589. 2017. View Article : Google Scholar : PubMed/NCBI
4	Zhang D, Park BM, Kang M, Nam H, Kim EJ, Bae C and Lim SK: The systemic effects of sclerostin overexpression using ΦC31 integrase in mice. Biochem Biophys Res Commun. 472:471–476. 2016. View Article : Google Scholar : PubMed/NCBI
5	Pietrzyk B, Smertka M and Chudek J: Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders. Adv Clin Exp Med. 26:1283–1291. 2017. View Article : Google Scholar : PubMed/NCBI
6	McDonald MM, Morse A, Birke O, Yu NYC, Mikulec K, Peacock L, Schindeler A, Liu M, Ke HZ and Little DG: Sclerostin antibody enhances bone formation in a rat model of distraction osteogenesis. J Orthop Res. 36:1106–1113. 2018.
7	McClung MR: Sclerostin antibodies in osteoporosis: Latest evidence and therapeutic potential. Ther Adv Musculoskelet Dis. 9:263–270. 2017. View Article : Google Scholar : PubMed/NCBI
8	Mirza FS, Padhi ID, Raisz LG and Lorenzo JA: Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 95:1991–1997. 2010. View Article : Google Scholar : PubMed/NCBI
9	Kim RY, Yang HJ, Song YM, Kim IS and Hwang SJ: Estrogen modulates bone morphogenetic protein-induced sclerostin expression through the Wnt signaling pathway. Tissue Eng Part A. 21:2076–2088. 2015. View Article : Google Scholar : PubMed/NCBI
10	Huang JM, Bao Y, Xiang W, Jing XZ, Guo JC, Yao XD, Wang R and Guo FJ: Icariin regulates the bidirectional differentiation of bone marrow mesenchymal stem cells through canonical Wnt signaling pathway. Evid Based Complement Alternat Med. 2017:80853252017. View Article : Google Scholar
11	Wu T, Shu T, Kang L, Wu J, Xing J, Lu Z, Chen S and Lv J: Icaritin, a novel plant-derived osteoinductive agent, enhances the osteogenic differentiation of human bone marrow- and human adipose tissue-derived mesenchymal stem cells. Int J Mol Med. 39:984–992. 2017. View Article : Google Scholar : PubMed/NCBI
12	Wang ZQ and Lou YJ: Proliferation-stimulating effects of icaritin and desmethylicaritin in MCF-7 cells. Eur J Pharmacol. 504:147–153. 2004. View Article : Google Scholar : PubMed/NCBI
13	Baron R and Gori F: Targeting WNT signaling in the treatment of osteoporosis. Curr Opin Pharmacol. 40:134–141. 2018. View Article : Google Scholar : PubMed/NCBI
14	Sheng H, Rui XF, Sheng CJ, Li WJ, Cheng XY, Jhummon NP, Yu YC, Qu S, Zhang G and Qin L: A novel semisynthetic molecule icaritin stimulates osteogenic differentiation and inhibits adipogenesis of mesenchymal stem cells. Int J Med Sci. 10:782–789. 2013. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
16	Harrison G, Shapiro IM and Golub EE: The phosphatidylinositol-glycolipid anchor on alkaline phosphatase facilitates mineralization initiation in vitro. J Bone Miner Res. 10:568–573. 1995. View Article : Google Scholar : PubMed/NCBI
17	Orimo H: The mechanism of mineralization and the role of alkaline phosphatase in health and disease. J Nippon Med Sch. 77:4–12. 2010. View Article : Google Scholar : PubMed/NCBI
18	Zhao Z, Zhao M, Xiao G and Franceschi RT: Gene transfer of the Runx2 transcription factor enhances osteogenic activity of bone marrow stromal cells in vitro and in vivo. Mol Ther. 12:247–253. 2005. View Article : Google Scholar : PubMed/NCBI
19	Taylor S, Hu R, Pacheco E, Locher K, Pyrah I, Ominsky MS and Boyce RW: Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized rats. Bone Rep. 8:95–103. 2018. View Article : Google Scholar : PubMed/NCBI
20	Zhao W, Li X, Peng Y, Qin Y, Pan J, Li J, Xu A, Ominsky MS, Cardozo C, Feng JQ, et al: Sclerostin antibody reverses the severe sublesional bone loss in rats after chronic spinal cord injury. Calcif Tissue Int. 103:443–454. 2018. View Article : Google Scholar : PubMed/NCBI
21	Bhattacharyya S, Pal S and Chattopadhyay N: Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action. Eur J Pharmacol. 826:39–47. 2018. View Article : Google Scholar : PubMed/NCBI
22	McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, et al: Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 370:412–420. 2014. View Article : Google Scholar : PubMed/NCBI
23	Lewiecki EM: Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther Adv Musculoskelet Dis. 6:48–57. 2014. View Article : Google Scholar : PubMed/NCBI
24	Mbalaviele G, Sheikh S, Stains JP, Salazar VS, Cheng SL, Chen D and Civitelli R: Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem. 94:403–418. 2005. View Article : Google Scholar
25	Datta I, Bhadri N, Shahani P, Majumdar D, Sowmithra S, Razdan R and Bhonde R: Functional recovery upon human dental pulp stem cell transplantation in a diabetic neuropathy rat model. Cytotherapy. 19:1208–1224. 2017. View Article : Google Scholar : PubMed/NCBI
26	Heidrich K, Thiede C, Schäfer-Eckart K, Schmitz N, Aulitzky WE, Krämer A, Rösler W, Hänel M, Einsele H, Baldus CD, et al: Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations. Ann Oncol. 28:2793–2798. 2017. View Article : Google Scholar : PubMed/NCBI
27	Wang Z, Wang D, Yang D, Zhen W, Zhang J and Peng S: The effect of icariin on bone metabolism and its potential clinical application. Osteoporos Int. 29:535–544. 2018. View Article : Google Scholar